Clinical Trials Logo

Filter by:
NCT ID: NCT05733689 Not yet recruiting - Clinical trials for Gastroesophageal Adenocarcinoma

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

Start date: February 2025
Phase: Phase 1
Study type: Interventional

This is a phase 1b prospective, single arm, open-label trial determining the efficacy and feasibility of using a ctDNA assay (test) result to help guide neoadjuvant chemotherapy in subjects with Stage IB, II or Stage III adenocarcinoma of the stomach or gastroesophageal junction (GEA).

NCT ID: NCT05733598 Not yet recruiting - Clinical trials for Recurrent Hepatocellular Carcinoma

RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, 2-cohort clinical study evaluating RP3 in combination with atezolizumab plus bevacizumab as First- or Second-line Systemic Therapy in patients with locoregionally advanced and/or metastatic Hepatocellular Carcinoma not amenable to surgical resection or standard locoregionally directed therapies.

NCT ID: NCT05733221 Not yet recruiting - Mandible Fracture Clinical Trials

3D Printed Models for Mandibular Fracture Repair

Start date: March 2023
Phase: N/A
Study type: Interventional

The investigators will test the hypothesis that patients randomized to the intervention (3D printing with pre-bent plate) arm have less operative room time and less time for the critical part of the procedure than patients in the control arm (no 3D printing, current standards of care). Personalized medicine and care for fracture treatment.

NCT ID: NCT05732779 Not yet recruiting - Health Behavior Clinical Trials

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

Start date: March 31, 2024
Phase: N/A
Study type: Interventional

We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.

NCT ID: NCT05732415 Not yet recruiting - Clinical trials for Multiple System Atrophy

Biomarker Study of ATH434 in Participants With MSA

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy

NCT ID: NCT05730283 Not yet recruiting - Clinical trials for Ototoxicity, Drug-Induced

Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to test the effectiveness of the study drug, ORC-13361, in preventing hearing loss in patients with NTM infection who are undergoing treatment with IV amikacin therapy. The main question this study aims to answer is: - Is ORC-13661 effective for preventing or lessening hearing loss induced by amikacin treatment? - Is ORC-13661 effective for preventing or lessening other measures of hearing impairment? Participants will be asked to take a study drug while they are being treated with IV amikacin. Participants will take study drug for 90 days or until the end of their amikacin treatment, whichever comes first. During this time, researchers will gather clinical data on the participants' health. Researchers will compare three groups - two groups taking different doses of the study drug and one group taking a placebo drug - to see if dose of drug has any effect on preventing hearing loss. A placebo is a look-alike substance that contains no active drug.

NCT ID: NCT05729516 Not yet recruiting - Type 2 Diabetes Clinical Trials

The Hope App Study

Start date: January 2024
Phase: N/A
Study type: Interventional

This research study will test how a computer program (called the Hope App) teaches diabetes care skills for older adults with diabetes. The study will compare those who receive diabetes education (10 educational modules and monthly health coaching) through the research program with those who receive care as usual.

NCT ID: NCT05728879 Not yet recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution

Start date: January 2025
Phase: Early Phase 1
Study type: Interventional

This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.

NCT ID: NCT05727761 Not yet recruiting - Oral Leukoplakia Clinical Trials

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Start date: June 15, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12 week course of twice daily pioglitazone-metformin. Outcomes are defined as are a reduction of the leukoplakia grade in > 50% of treated participants and a partial or complete clinical response defined as 50% or greater reduction in the sum of measured targeted lesions. In addition, participants who show clinical and histologic improvement should correlate with a significant reduction of Ki-67 proliferative indices in lesions of these participants as compared to baseline.

NCT ID: NCT05727657 Not yet recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Satralizumab in Aneurysmal Subarachnoid Hemorrhage

SASH
Start date: July 1, 2024
Phase: Early Phase 1
Study type: Interventional

In this study, satralizumab will be administered to see whether satralizumab is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.